Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

Stock Information for Vivakor Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vivakor Inc.

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HRT, NX, AKTX
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.